Alpha-1A adrenergic receptor and Alpha-1D adrenergic receptor (α1A-AR and α1D-AR)

Alpha-1A adrenergic receptor and alpha-1D adrenergic receptor are subtypes of the alpha-1 adrenergic receptor family, which are G protein-coupled receptors responsive primarily to catecholamines such as norepinephrine and epinephrine[1][2][3]. These receptors are primarily expressed in smooth muscle cells of blood vessels and the lower urinary tract, where they mediate vasoconstriction and increase peripheral vascular resistance, playing a crucial role in the regulation of blood pressure[2][3][7]. The alpha-1A subtype is particularly involved in prostatic smooth muscle contraction and is a key target for the treatment of benign prostatic hyperplasia, while the alpha-1D subtype is implicated in vascular and urinary tract functions[3][7]. Drugs targeting these receptors include vasoconstrictors (agonists) and alpha-blockers (antagonists) used to treat hypertension, heart failure, and urinary retention diseases[7][3][4]. Recent structural studies have provided insights for rational drug design with improved selectivity and fewer side effects[1][2]. Both subtypes belong to the class of seven-transmembrane domain GPCRs that signal via the Gq/11 protein pathway, activating phospholipase C and elevating intracellular calcium to produce their downstream effects[3][2][7]. They are broadly considered key therapeutic targets in cardiovascular and urologic diseases.

Other names

α1A-adrenoceptorα1A-ARalpha-1A-adrenoceptorα1D-adrenoceptorα1D-ARalpha-1D-adrenoceptorAlpha-1 adrenergic receptor subtypes

Agonists stimulate the receptor causing vasoconstriction and increased smooth muscle contraction (via Gq/11 pathway, leading to increased intracellular calcium)[1][2][3][7]. Antagonists (alpha-blockers) inhibit the receptor, leading to vasodilation, decreased peripheral resistance, lowered blood pressure, and relaxation of smooth muscle in the urinary tract[7][3].